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ABSTRACT
Centrosome amplification (CA), a cell-biological trait, characterizes pre-neoplastic 
and pre-invasive lesions and is associated with tumor aggressiveness. Recent studies 
suggest that CA leads to malignant transformation and promotes invasion in mammary 
epithelial cells. Triple negative breast cancer (TNBC), a histologically-aggressive 
subtype shows high recurrence, metastases, and mortality rates. Since TNBC and non-
TNBC follow variable kinetics of metastatic progression, they constitute a novel test bed 
to explore if severity and nature of CA can distinguish them apart. We quantitatively 
assessed structural and numerical centrosomal aberrations for each patient sample in a 
large-cohort of grade-matched TNBC (n = 30) and non-TNBC (n = 98) cases employing 
multi-color confocal imaging. Our data establish differences in incidence and severity 
of CA between TNBC and non-TNBC cell lines and clinical specimens. We found strong 
correlation between CA and aggressiveness markers associated with metastasis in 
20 pairs of grade-matched TNBC and non-TNBC specimens (p < 0.02). Time-lapse 
imaging of MDA-MB-231 cells harboring amplified centrosomes demonstrated enhanced 
migratory ability. Our study bridges a vital knowledge gap by pinpointing that CA 
underlies breast cancer aggressiveness. This previously unrecognized organellar 
inequality at the centrosome level may allow early-risk prediction and explain higher 
tumor aggressiveness and mortality rates in TNBC patients.
INTRODUCTION
As the name foretells, triple-negative breast cancers 
(TNBC) do not over-express the estrogen, progesterone, 
or Her2 receptors, thus precluding patient response to 
several targeted therapies available in the clinic. More so, 
TNBC preferentially afflicts women of African descent 
and is characterized by high aggressiveness, recurrence, 
metastases and mortality rates [1–3]. About 40% of all 
breast cancer cases in pre-menopausal AA patients are TN 
(5-year survival of ~80% as opposed to ~90% in European 
American patients), putting this patient subgroup at a 
higher risk for poorer outcomes [4].
Recent literature points out an intriguing correlation 
between BRCA1 (breast cancer suppressor gene 1) 
mutation carriers and TNBC status. About 70% of women 
with breast cancer carrying a BRCA1 mutation belong to 
the triple-negative subtype [5]. Beyond a crucial role of 
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BRCA1 in regulating centrosome duplication, BRCA1 
is also known to interact with a variety of proteins that 
regulate centrosome duplication, including BRCA2 (breast 
cancer suppressor gene 2), CDK2/Cyclin A, CDK2/
Cyclin E, Gadd45, p21, p53 and Rb [6–8]. Furthermore, 
targeted disruption of BRCA1 results in centrosome 
amplification (CA), confirming that BRCA1 serves as 
a negative regulator for centrosome duplication [9]. 
These data are consistent with the notion that BRCA1 
and BRCA2 tumor suppressor genes directly maintain 
genomic stability, and affirm a causative link between 
BRCA1 mutations and centrosomal overload that is 
associated with extensive chromosomal instability (CIN) 
found in TNBC patients. Therefore, amplified centrosomes 
may present a fascinating, readily quantifiable prognostic 
marker and druggable target for TNBCs, currently plagued 
by insufficiency of molecular targets that precludes their 
treatment and optimal management.
Centrosomal abnormalities and CIN strongly 
characterize pre-invasive in situ ductal carcinomas, thus 
incriminating these anomalies in fueling tumor progression 
and metastases. Thus far, a thorough quantitative 
comparison of centrosomal aberrations in breast tumor 
subtypes with inherently different metastatic capability has 
never been reported. Herein, we performed a comprehensive 
quantitative analysis of centrosomal abnormalities in 
breast tumors to establish differences in incidence and 
severity of CA (structural and numeral) between grade-
matched TNBC (n = 30) and non-TNBC (n = 98) patients. 
Intriguingly, we found significant correlation of CA status 
with patient outcomes wherein we ascertained that patients 
exhibiting higher centrosome aberrations (> 20%) had 
lower Progression free survival (PFS) than patients with 
lower centrosome aberrations (< 20%). We also established 
a strong association between CA markers and markers of 
breast tumor aggressiveness, suggesting that robust CA 
underlies acquisition of aggressive phenotypes.
Our results generate compelling foregrounds to 
establish CA as a quantifiable property of low-grade tumors 
that can predict the risk of a tumor being or becoming an 
aggressive one. A validated method to quantify this cell-
biological cancer-specific organellar trait can provide 
clinicians with a method to stratify low-grade tumors into 
high- and low-risk subgroups and may enable channeling 
of patients into optimal treatment paths to reduce existing 
disparities in breast cancer patient outcomes.
RESULTS
In silico overexpression of CA-associated genes 
is correlated with reduced survival and triple-
negative subtype
Previous studies in solid tumors have alluded to 
an association between centrosomal abnormalities and 
advanced disease, aneuploidy, and an aggressive clinical 
course. These studies however lacked rigorous quantitation 
of the centrosomal abnormalities and have not explored 
whether centrosomal abnormalities are accompanied by 
any changes in the expression patterns of centrosomal 
genes. Given that there are differences in aggressive 
behavior between TNBC and non-TNBC patients, we 
investigated whether these histologically-distinct breast 
cancer subtypes might differ in the expression levels of 
centrosomal genes. To this end, we mined publically-
available microarray data of breast cancer patients to 
evaluate gene expression levels for major structural 
centrosomal proteins, both centriolar (centrin) and 
pericentriolar (pericentrin and γ-tubulin). To gain deeper 
insights into centrosomal aberrations, we included 
genes whose dysregulation is implicated in CA (polo-
like kinase 4 and cyclin E). We calculated a cumulative 
gene expression-based centrosome amplification index 
(CAI) by adding log transformed, normalized gene 
expression for CETN2 (centrin-2), TUBG1 (γ-tubulin), 
PCNT2 (pericentrin), PLK4 (polo-like kinase 4) and 
CCNE1 (cyclin E) genes. Given that cancer is a clonally 
evolving disease and CA could arise due to dysregulation 
of different genes in different cancers and even distinct 
cancer cell clones, we chose to select a panel of five 
centrosomal genes instead of a single gene. First, we 
evaluated the relationship of higher CA, as assessed by 
CAI, with disease aggressiveness, as determined by 
overall survival (OS). OS was calculated as the number 
of days from diagnosis to death or last follow-up if death 
was not recorded. Irrespective of receptor status (TNBC 
n = 101, non-TNBC n = 61), patients with higher CAI 
(n = 78) had lower OS (p = 0.049) than patients with lower 
CAI (n = 84) (Fig. 1A). Intriguingly, high CAI group was 
composed of ~60% TNBC cases whereas the low CAI 
group composed of ~38% TNBC cases, thus indicating 
that TNBCs tend to have higher CAI as compared to non-
TNBCs. Further analysis of another dataset of 138 TNBC 
and 466 non-TNBC samples clearly showed significantly 
higher CAI in TNBCs compared to non-TNBCs, even 
when they were (a) grade-matched (Fig. 1B), or (b) stage-
matched (Fig. 1C).
In sum, these data suggest that more aggressive 
disease course in TNBC is accompanied by significant 
overexpression of centrosomal genes. Additionally, 
overexpression of centrosomal genes is strongly associated 
with poorer OS.
TNBC patients have higher centrosome 
amplification than non-TNBC
Our in silico data analysis yielded significantly 
elevated CAI in TNBC women compared to non-TNBC. 
Thus, we visualized amplified centrosomes in grade-
matched tissues from TNBC (n = 59) and non-TNBC 
(n = 116) patients (Fig. 2A) employing multicolor 
confocal immunofluorescence microscopy. Centrosomes 
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were labelled by γ-tubulin (green) antibody, wherein 
centrosomal aberrations were determined by abnormal 
number of γ-tubulin spots (more than two) as well as by 
increased volume over normal centrosomal volume in 
breast epithelial cells from normal adjacent tissues. Fig. 2A 
shows representative confocal immunomicrographs 
depicting centrosomes (γ-tubulin, green) and nuclei 
(DAPI, blue) from normal breast tissue and breast cancer 
tissue from grade-matched (Grade II) TNBC and non-
TNBC patients. Cells with more than two centrosomes 
were estimated by examining and counting centrosomes 
in atleast 500 cells/slide. Fig. 2B shows that the number 
of cells harboring extra centrosomes were twice as much 
higher in TNBC samples (62, n = 30) versus non-TNBC 
(30, n = 98) (p < 0.05) in a grade-matched background. 
We next measured centrosomal volumes in all specimens 
using the three-dimensional measurement module from 
the Zeiss imaging software. While mean centrosomal 
volume in normal breast epithelial cells was 0.22 μm3 
(ranging from 0.08 to 0.76 μm3), the mean volume of 
γ-tubulin-stained spots analyzed in at least 500 tumor 
cells from each patient sample was 4.85 μm3, which is ~15 
times higher than the centrosomal volume in normal cells. 
Fig. 2C shows that centrosome volume was significantly 
higher in TNBC samples (n = 30) (average = 6.8 μm3) 
compared to grade-matched (Grade II) non-TNBC (n = 98) 
samples (average = 4.2 μm3) (p < 0.05). Additionally, 
we calculated the total centrosome amplification as a 
percentage by adding percent cells harboring more than 
two centrosomes and percent cells harboring centrosomes 
with volume larger than 0.76 μm3. Our analysis revealed 
that on an average, ~68% of cells in TNBC samples 
exhibited centrosome amplification as compared to ~45% 
in non-TNBC samples (p < 0.05).
We next compared the expression levels of 
centrosomal proteins (centrin-2 and γ-tubulin) in fresh-
frozen tumors and uninvolved adjacent tissue from 
20 pairs of grade-matched TNBC and non-TNBC 
patients. Immunoblotting of tissue lysates showed 
higher expression of two centrosomal proteins (centrin-2 
and γ-tubulin) in TNBC than in non-TNBC patients 
(Fig. 3A). In addition, breast cancer cell lines derived 
from TNBC patients (MDA-MB-468, MDA-MB-231) 
showed (a) higher incidence and severity of centrosome 
amplification (Fig. 3Ci, ii) (b) elevated expression 
of centrosomal (pericentrin, centrin-2, γ-tubulin) and 
centrosome amplification markers (Plk4 and cyclin E), 
compared to non-TNBC-derived (MCF-7) lines (Fig. 3B). 
Intriguingly, the extent of amplification was considerably 
lower in cell lines (5–30%) compared to patient tissue 
samples  (15–80%), irrespective of the receptor status. 
This observation highlights a previously unrecognized 
discordance between human tumor tissues and established 
cell lines. This also underscores the limitations of in vitro 
cell lines as a model system for establishing and testing 
centrosome-targeted therapies.
Centrosome amplification status correlates 
strongly with metastatic disease and progression-
free survival in patient samples
We next evaluated expression levels of molecules 
implicated in CA by immunohistochemical staining 
of paraffin-embedded tumor and uninvolved adjacent 
tissue in 20 pairs of grade-matched (Grade II) TNBC 
and non-TNBC samples. Immunohistochemical data 
strongly suggested overexpression of well-established 
centrosome amplification markers (Aurora-A and Plk4) in 
TNBC compared to non-TNBC samples (Fig. 4A). The 
same samples were also immunostained for vimentin, a 
breast cancer aggressiveness marker. As expected, TNBC 
samples exhibited significantly higher expression of 
vimentin (Fig. 4B). Representative images of two sets 
of grade-matched breast tumor samples (one TNBC, 
one non-TNBC) exhibiting different expression levels 
of centrosomal proteins, show that TNBC samples 
Figure 1: Breast tumors with higher CAI have lower survival rate compared to low CAI tumors. A. Overall survival 
plots for high and low CAI groups. High CAI patients had lower overall survival (n = 84) compared to low CAI patients (n = 78) in in silico 
data. B. Scatter-plot comparing the CAI in TNBC and grade-matched non-TNBC patients (p < 0.001 for Grade II TNBC and non-TNBC 
patients). C. Bar graphs comparing the CAI in TNBC and non-TNBC patients considering stages (p < 0.005 for stage-matched TNBC 
and non-TNBC patients). (Lower n number in the survival analysis is due to the limited availability of survival data for all patients in the 
referred databases.)
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exhibited higher expression levels of these proteins 
than non-TNBC samples and normal tissue (Fig. 4A). 
Statistical analysis of 20 pairs of grade-matched TNBC 
and non-TNBC samples revealed a strong positive 
correlation between Plk4 and vimentin (r = 0.58, 
p < 0.02). Immunoblots shown in Fig. 4C also support 
our observation that centrosomal markers (Aurora-A, 
Plk4 and cyclin E) exhibit similar expression patterns and 
trends as metastasis markers (vimentin) in breast tumor 
samples. Furthermore, we evaluated the relationship of 
higher centrosome aberrations (as assessed by %CA in 
Fig. 2Bi) with progression-free survival (PFS) in breast 
cancer patients. PFS was calculated as the number of days 
from diagnosis to the first local recurrence or metastasis 
(if one occurred), or the last follow-up if the patient did 
not progress. Irrespective of receptor status (n = 120), 
patients with higher centrosome aberrations (> 20%) had 
lower PFS (p < 0.08) than patients with lower centrosome 
aberrations (< 20%) (Fig. 4D). Interestingly, a majority 
(~72%) of high CA (high-risk) group were TNBC while 
low CA (low-risk) group were largely non-TNBC (~60%).
Cells with supernumerary centrosomes 
show higher migration velocity and net 
displacement compared to cells with 
normonumerary centrosomes
We next asked if extra centrosomes were 
associated with enhanced cell migration. To discern 
this, we performed a cell migration assay using time-
lapse imaging wherein migration of MDA-MB-231 cells 
(stably transfected with GFP-tagged centriolar protein, 
Figure 2: Comparison of extent of centrosome amplification in grade-matched TNBC and non-TNBC patients.  
A. Representative confocal micrographs depicting the status of centrosome amplification in histological Grade I, Grade II and Grade III 
TNBC and non-TNBC tissues. Centrosomes were labelled with γ-tubulin antibody (green) and DNA was stained with DAPI (blue) Yellow 
arrows indicate numerical amplification and white arrows indicate structural amplification. Scale bar 5 μm. B. Bar graph representation 
of number of cells out of 500 showing supernumerary centrosomes (> 2 or ≤ 2) in TNBC and non-TNBC tissue samples. C. Box whisker 
graph representation of average volume of centrosomes in normal, TNBC and non-TNBC tissue samples. At least 500 cells were counted 
in each case (ANOVA, p < 0.05).
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Figure 3: TNBC tumors and cell lines show higher expression of centrosomal markers. A. Immunoblots for 5 paired 
breast tumor (T) and normal adjacent (N) tissues from grade-matched TNBC and non-TNBC patients showing expression levels of 
centrosomal markers. B. Immunoblots of centrosomal markers in MCF-7 (non-TNBC), MDA-MB-468 and MDA-MB-231 (TNBC) cell 
lines. Ci. Immunofluorescence micrographs showing MCF-10A cells (near-normal), MCF-7 cells (non-TNBC) and MDA-MB-468 and 
MDA-MB-231 cells (TNBC) in interphase and mitotic state, stained for γ-tubulin (green), α-tubulin (red) and DAPI (blue). Cii. Bar graph 
quantitation of percent cells depicting multipolar mitosis and centrosomal amplification in interphase in MCF-7 (non-TNBC) and MDA-
MB-468 and MDA-MB-231 (TNBC) cell lines. (Only Grade II TNBC and non-TNBC samples were matched because of limited n numbers 
for Grade I TNBC and Grade III non-TNBC samples in our dataset.)
Figure 4: Breast tumors in TNBC patients show higher expression of centrosomal proteins and aggressiveness 
markers. A. Micrographs showing immunohistchemical staining for Aurora-A, Plk4 (centrosomal amplification markers) and vimentin 
(breast cancer metastasis marker) in normal and cancer tissue from representative grade-matched TNBC (2170) and non-TNBC (6456) 
patients. B. Box whisker graph showing significantly higher expression of vimentin in TNBC samples when compared to grade-matched 
non-TNBC samples. C. Immunoblots for normal, TNBC (2170) and non-TNBC (6456) tissue samples showing Aurora-A, Cyclin E and 
vimentin expression. D. Progression free survival (PFS) plot for the patients with higher (> 20%) CA (red) and lower (< 20%) CA (blue). 
(Only Grade II TNBC and non-TNBC samples were matched because of limited n numbers for Grade I TNBC and Grade III non-TNBC 
samples in our dataset.)
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centrin) harboring 1 centrosome or > 2 centrosomes 
was observed. Fig. 5A shows representative data for 
a pair of cells observed upon 18 h time-lapse imaging, 
where a cell with 1 centrosome migrated from a to a’ 
(Fig. 5Ai) and a cell with 4 centrosomes moved from 
b to b’ (Fig. 5Aii). Quantitation of merged time-lapse 
sequences (10 min apart, collected over 18 h) showed 
higher average net displacement (78%), displacement 
rate (55%) and track velocity (~2 fold enhancement) 
of cells with > 2 centrosomes compared to cells with 
1 centrosome (Fig. 5Bi,ii,iii). These data strongly suggest 
that overabundance of centrosomes enhances migratory 
ability in cancer cells. Having established a strong 
correlation between extra centrosomes and cell migration 
in MDA-MB-231, an aggressive breast cancer cell line, 
we next asked if centrosome amplification directly and 
independently impacted the migration potential of a near-
normal immortalized breast epithelial cell line, MCF-10A. 
We evaluated if generation of extra centrosomes by genetic 
means will impact migration and invasion kinetics in 
breast epithelial cells. To this end, we used MCF-10A cells 
engineered to facilitate inducible overexpression of wild-
type Plk4 or truncated Plk4 (1-608, negative control), upon 
doxycycline treatment for 48 h. CA induced 48 h after 
Plk4 induction was confirmed by immunofluorescence 
staining for γ-tubulin (green) (data not shown) and 
change in γ-tubulin levels by immunoblotting in cells 
overexpressing wild-type Plk4 (denoted as Plk4 OE in 
Fig. 5C, whereas no amplification was observed in cells 
overexpressing truncated Plk4 (denoted as C in Fig. 5C). 
We also observed a significant increase in vimentin levels 
along with centrosomal proteins upon doxycycline-based 
induction of CA (Fig. 5C). We then performed a classical 
wound healing assay to assess the migratory capacity of 
cells with amplified centrosomes (~80% cells harboring 
extra centrosomes) as compared to the control cells. We 
found that cells with CA filled the scratch wound in less 
than half the time as control cells (28 h as compared 
to 60 h) (Fig. 5D). Additionally, an increase in the 
invasion capacity of wild-type Plk4 overexpressing cells 
was observed in a Boyden chamber assay. Fig. 5E shows 
that a significantly higher number of cells invaded the 
bottom chamber of the filter after 48 h of incubation. We 
also confirmed these observations by inducing centrosome 
amplification via pharmacological manipulation. We 
experimentally induced centrosome amplification in 
MDA-MB-231 cells by aphidicolin treatment (5 μg/ml 
for 48 h). Centrosome amplification upon treatment was 
confirmed by immunofluorescence staining for γ-tubulin 
(Suppl. Fig. 1A). An increase in the invasion capacity 
of treated cells was observed via Boyden chamber assay 
(Suppl. Fig. 1B).
These data collectively underscore the critical role 
of centrosomes in facilitating directed cell migration 
Figure 5: Cells with amplified centrosomes show higher migration. Ai, ii. Time lapse images over 18 h of GFP-centrin-MDA-
MB-231 cells with one (i-top panel) versus four (ii-bottom panel) centrosomes. Trajectories of 10 cells each were captured over 18 h 
(6 frames/h). Data was analyzed using Volocity 3.0 software and average net displacement, displacement rate and velocity measurements 
were generated for the respective cells with respect to cell centroids. Scale bar 10 μm. Quantitation of net displacement Bi. displacement 
rate Bii. track velocity Biii. for cells with 1 and > 2 centrosomes are shown in bar graphs. Track velocity is the rate at which the cell traces 
the entire path between point a and a’. Displacement rate is the rate at which cell covers the distance from point a to a’. C. Immunoblots 
showing protein expression levels of γ-tubulin, centrin and vimentin in MCF-10A cells expressing either inducible truncated Plk4 (denoted 
as C) or inducible wild-type Plk4 (denoted as Plk4 OE). D. Brightfield microscopic images showing wound healing capacity of MCF-10A 
cells expressing either inducible truncated Plk4 (denoted as Control) or inducible wild-type Plk4 (denoted as Plk4 OE) at 0 h and 28 h. 
Scale bar 10 μm. E. Bar graph showing the number of invaded cells in Boyden chamber assay performed with control (truncated Plk4) and 
wild-type Plk4 overexpressing MCF-10A cells. CTR = centrosomes.
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and invasion. These observations lay the experimental 
foundation that link CA, an important cellular feature 
of certain cancers, to more aggressive phenotypes and 
provide a tantalizing possibility that organellar-level 
differences may serve as a risk predictor of aggressiveness 
in breast cancer patients.
DISCUSSION
A century ago, Theodore Boveri proposed that 
subtle mitotic errors in dividing cells are responsible for 
generating aneuploidy and chromosomal instability, and 
thus propelling tumorigenesis [10]. This pioneering theory 
originated from his observations that increased number 
of centrosomes lead to multipolar mitosis and highly 
aneuploid daughter cells. Since then, several landmark 
studies have demonstrated that the centrosome plays an 
important role in erection of a fusiform spindle apparatus 
that ensures high-fidelity chromosome segregation to 
produce two genetically-identical progeny cells [11, 12]. 
It is now well-established that abnormal number of 
centrosomes most often result in aberrant mitotic divisions 
and aneuploidy, all of which are frequently observed in 
many solid and hematological human cancers [13–18].
In addition, chromosomal instability underlies 
generation of aneuploidy over time, and has been 
associated with various prognosticators in breast cancer. 
All these studies point towards a strong correlation 
between centrosome amplification and tumor progression, 
recurrence and poor survival yet the mechanistic aspects 
of this relationship have remained elusive. Recently, 
Godinho et al. provided convincing cell-based evidence to 
prove that centrosome amplification can cause oncogene-
like effects to promote cellular invasion in mammary 
epithelial cells [19]. These findings assert that cytoskeletal 
modifications at the structural level driven by centrosome 
amplification engenders transformation potential in normal 
epithelial cells and is directly responsible for tumor 
initiation and progression. This study clearly substantiates 
our published hypothesis that cells endowed with extra 
centrosomes possess a cytoskeletal edge over other cells, 
thus imparting enhanced cell polarization, Golgi-mediated 
vesicular trafficking and invasion potential, leading to 
increased metastatic progression.
Indeed, a miscellany of centrosomal defects 
such as increase in number, size, and atypical structure 
comprise centrosome amplification. Centrosomal 
amplification in human cancers is of two kinds: structural 
and numerical [20, 21]. Structural defects can be due to 
abnormal centriole structure and/or abnormal amount 
of pericentriolar material (PCM). While detection of 
alterations in centriole size is precise using centriole-
specific antibody, an increased amount of PCM, detected 
by a pericentriolar antibody, can present complex 
ambiguous scenarios. One possibility is increased PCM, 
making it a ‘true structural defect’. Another possibility is 
that supernumerary centrosomes that are tightly clustered 
during interphase may appear as a large centrosome, 
and thus in fact appear to be a ‘structural defect’. In 
several cases, one can notice supernumerary centrosomes 
with increased PCM, making it both a structural and 
numerical defect. These issues render quantitation of 
centrosomal defects very subjective and dependent 
on the viewer’s discretion. Therefore, better methods 
to systematically assess and distinguish centrosome 
abnormalities are much needed. Numerical defects in 
the form of centrosome amplification have been widely 
described in human cancer, but not much is known about 
the structural defects. It is reasonable to speculate that 
both numerical and structural defects may distinctly 
shape the course of tumor progression. We reason that 
in low grade tumors, numerical defects that manifest 
as amplified centrosomes may advantageously serve 
cancer cells during an erroneous mitosis by offering 
them a means to generate an array of clones that form 
the basis of intratumor heterogeneity, the Holy Grail 
of cancer chemotherapy. Once these heterogeneous 
clones attain desirable karyotypes, we conjecture that 
individual centrosomes tend to cluster which may endow 
cells with cytoskeleton-derived mechanical advantages 
for directional migration. This might partly explain 
why certain non-invasive lesions transform into highly 
aggressive tumors with metastatic capabilities while others 
tend to remain indolent. This is in consonance with the 
fact that an increased centrosomal complement displays 
an augmented microtubule nucleation capacity [13]. 
We envision that a higher microtubular density in 
cancer cells in conjunction with the action of the actin 
cytoskeleton may provide cells with protrusion capability 
for faster migration through the ECM [22]. Centrosomes 
and the microtubules they nucleate together establish 
the nuclear-centrosomal axis, which defines direction 
of cell movement, and controls post-mitotic Golgi 
reassembly [23]. Essentially, microtubules nucleated on 
the juxta-centrosomal Golgi serve as tracks for Golgi-
derived vesicles carrying proteins essential for leading 
edge protrusion, and matrix remodeling [22]. Our data 
in MDA-MB-231 cells (where 20–30% of cells display 
CA) showed that cells with extra centrosomes migrate 
~2-fold faster than cells with normal centrosome number 
(Fig. 5A, 5B). In addition to facilitating faster cellular 
movement, it is likely that supernumerary centrosomes 
may impart cells with an enhanced stroma-penetrating 
capacity through an inventory of mechanisms including 
augmentation of microtubule-dependent MMP secretion.
Currently-used prognostic indicators in breast 
cancer (e.g. Ki67) do not predict metastases risk 
accurately in early- tumors. Expensive commercial 
multigene expression assays such as OncotypeDx 
provide a “Recurrence Score” and while treatment paths 
for patients with scores < 18 (low-risk) and > 31 (high-
risk) are relatively unambiguous, 34% of patients with 
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scores between 18–31 lack additional markers to guide 
optimal [24]. Given that breast cancers harbor amplified 
centrosomes, a quantitative estimation of centrosomal 
abnormalities in fine-needle aspirates or paraffin-
embedded samples may prove to be a simple, sensitive, 
and easily quantifiable risk-predicting biomarker.
Precise prognosis suffers challenges owing to 
various confounding factors with bearing on breast 
cancer patient outcomes such as race, age, receptor-
status, molecular signatures and so on. For instance, 
among African-American women with breast cancer, 
there is an estimated 20–40% chance of the breast cancer 
being triple-negative [4, 25]. It is well known that TNBC 
accounts for ~15% of all breast cancer in the United 
States. It seems to be more common in (a) young women, 
(b) women of African ancestry, and (c) individuals with 
BRCA1 mutations [26]. Cancer recurs in ~30% of TNBC 
patients at an early stage, typically within three to four 
years following treatment. Further studies are required 
to understand why premenopausal women and women in 
some ethnic groups have higher rates of triple-negative 
breast cancer than other groups of women, and what 
mechanisms underlie the aggressive traits of TNBCs. 
Such studies will be critical in order to device relevant 
treatment strategies specific for the particular group pf 
patients or tumor subtypes. However, finding suitable 
targeting pathways in TNBC is proving to be a challenge, 
particularly because these biologically aggressive tumors 
do not depend on one dominant pathway, unlike ER-
positive or Her2-positive tumors. Several studies have led 
to the realization that TNBC tumors are a mixed bag and 
this extensive heterogeneity reported in TNBC provides 
a strong indication that CA that underlies chromosomal 
instability driven karyotypic diversity could be the 
underlying cause of the aggressive nature of this breast 
cancer subtype. Recent reports focused on identifying 
the key genetic and molecular features of individual 
TNBC tumors led to the identification of 7 TNBC 
subtypes, as follows: basal-like 1 (BL1); basal-like 2 
(BL2); immunomodulatory (IM); mesenchymal (M); 
mesenchymal stem–like (MSL); luminal androgen receptor 
(LAR); and unstable (UNS) [27]. Such a classification 
based on differential gene and molecular expression is a 
significant effort in unmasking specific susceptibilities of 
tumors, which can be targeted for tailored therapies. While 
the enormous effort and cost associated with such gene 
expression based assays limit their feasibility and prompt 
use in the clinic, non-invasive centrosome-based detection 
methods (e.g. in fine-needle aspirate cytology) may allow 
early detection of fatal breast cancers and distinguish them 
from benign forms. Since majority of breast cancers are 
characterized by centrosome amplification, the extent, 
severity and type of amplification can provide insights 
into the metastatic propensity of certain tumors as opposed 
to others. In this study, we have clearly demonstrated a 
positive correlation between markers of centrosome 
amplification and vimentin expression in breast cancer 
patients. These data lay compelling grounds for the 
exploration of centrosomal defects as cell-biological traits 
of non-invasive lesions that can potentially determine 
metastatic risk and meaningfully contribute towards the 
dawn of precision medicine.
MATERIALS AND METHODS
In silico analysis of CAI
One channel microarray data were collected from 
Gene Expression Omnibus (GEO) database and Cancer 
Genome Atlas (TCGA) and processed using Robust 
Multiarray (RMA) normalization, and was further used 
for gene expression analysis. The lists of the GSE ID’s 
are given in Supplementary table 1. Log2n transformed 
expression levels of Plk4, Aurora-A, Centrin-2, 
γ-tubulin and pericentrin genes were extracted from 
the TCGA and GEO patients and a summation was 
calculated to generate a CAI for TNBC and Non-TNBC 
patients. Statistical analysis was performed using 
Student’s t-test. The criterion for statistical significance 
was p < 0.05.
Clinical tissue samples
Paraffin embedded slides were procured from 
Emory University Hospital and Northside Hospital with 
information on clinical outcomes. The Emory Institutional 
Review Board (IRB) and Northside Hospital approval 
was obtained for all aspects of the study. Twenty fresh-
frozen tissue samples for immunoblotting were procured 
from Meenakshi V. Gupta, West Georgia Hospital. All the 
tissue samples used were archived and de-identified, thus 
no patient consent was required.
Immunofluorescence, imaging and scoring
Tissue slides were de-paraffinized by baking 
at 67°C for 2 h followed by 3 xylene washes and 
rehydrated in a series of ethanol baths (100%, 95%, 
70% and 50%). Antigen retrieval was performed by 
citrate buffer (pH 6.0) in a pressure cooker for 3min. 
Primary antibody incubation was done overnight against 
γ-tubulin (1:1000) at 4°C. The samples were incubated 
with secondary antibody (Alexa-488 anti-mouse) at 
37°C for 2 h. Samples were washed 3x with PBS and 
then mounted with Prolong-Gold antifade reagent that 
contained DAPI (Invitrogen). Tissue samples were 
imaged using the Zeiss LSM 700 Confocal microscope 
(Oberkochen, Germany) and images were processed with 
Zen software (Oberkochen, Germany). Percentage cells 
with centrosomal abnormality were quantitated from 
10 randomly selected fields per sample (500 cells counted 
for each sample).
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Immunohistochemistry and scoring
Samples were processed in the same way till antigen 
retrieval as mentioned above in Immunofluorescence 
section. Tissues were then immunostained for vimentin, 
Plk4 and Aurora-A. To perform enzymatic antibody 
detection, Universal LSAB + kit/HRP (DAKO, CA, USA) 
was used. A relative intensity score was represented as 
0 = none, 1 = low, 2 = moderate, or 3 = high and frequency 
score was depicted as the percentage of cell nuclei or 
cytoplasm demonstrating vimentin positivity (i.e. a score 
of 1, 2, or 3). The product of intensity and frequency was 
measured as weighted index (WI) for both the nucleus and 
cytoplasm.
Three-dimensional volume measurement
10–15 fields of view within the stained tissue 
were imaged via laser scanning confocal microscopy 
(Zeiss, Oberkochen, Germany) and for each field, optical 
sections of 0.5 um thickness each are acquired. For 
each field of view, the optical sections are stacked to 
produce a “maximum intensity projection image”. The 
raw confocal images are then opened in a 3-D volume 
rendering software (Zeiss, Oberkochen, Germany) for 
determining the volumes of each centrosome present in 
each microscopic field. The volume range for a normal 
centrosome is determined by analyzing the volumes of 
at least 500 centrosomes from normal tissue of 3 normal 
breast tissues. The smallest and the largest value for 
centrosomal volume provide the normal centrosome 
volume range for that tissue.
Cell culture
MCF-7, MDA-MB-231 and MDA-MB-468 cells 
were purchased from ATCC. MCF-7cells were grown in 
MEM, MDA-MB-231 and MDA-MB-468 were grown in 
DMEM supplemented with 10% Hyclone Fetal Bovine 
serum and 1% penicillin/streptomycin and MCF-10-A 
were grown in MGEM (Lonza). All cell lines were 
maintained in 5% CO2 atmosphere at 37°C.
Cellular protein preparation, Immunoblot 
analysis, Immunofluorescence and antibodies
Protein lysates were prepared from ~70% confluence 
cells and frozen tissue samples (sonicated). Briefly, PAGE 
was used to resolve the proteins and transferred on to 
PVDF membrane (Millipore). Pierce ECL detection kit 
(Thermo Scientific) was used to visualize the immune-
reactive bands corresponding to respective primary 
antibodies. β-actin was used as loading control. For 
immunofluorescence staining, cells were grown on glass 
coverslips and fixed with ice cold methanol for 10 min. 
Blocking was done by incubating with 2% bovine serum 
albumin/PBS.0.05% Triton X-100 at 37°C for 1 h. Primary 
Antibodies against γ-tubulin, α-tubulin were incubated 
with coverslips for 1 h at 37°C at the dilution 1:2000.The 
cells were washed with 2% bovine serum albumin/PBS 
for 10 min at room temperature before incubating with a 
1:2000 dilution of Alexa 488- or 555-conjugated secondary 
antibodies Invitrogen (Carlsbad, CA, USA). Antibodies 
against γ- tubulin, α-tubulin and vimentin were from 
Sigma (St. Louis, MO, USA), Aurora-A, Plk4 and β-actin 
were from cell signaling, Centrin-2 and Cyclin E from 
Santacruz and Pericentrin-2 from Abcam. Horseradish 
peroxidase-conjugated secondary antibodies were from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Boyden chamber assay
MCF-10A cells overexpressing inducible Plk4 or 
truncated version of Plk4 (1-608) were collected after 24 h 
transfection and resuspended in media at 5 × 104 cells/ml 
density. Transmigration assay was carried out in a Boyden 
chamber system. Cells that had migrated to the bottom 
surface of the filter were fixed with 70% methanol, stained 
with crystal violet, and counted under a microscope in 
10 randomly selected fields at 20X magnification (Zeiss 
Axioplan).
Time-lapse imaging
Stably transfected centrin-GFP MDA-MB-231 
cells were plated at 60% confluence on Matek cell 
culture plates. Cells were then imaged using time-lapse 
microscopy at 40X magnification on PerkinElmer Ultra 
View ERS spinning disc microscope (Waltham, MA, 
USA). GFP images were captured at multiple points every 
10 min for 18 h. Captured images from each experiment 
were analyzed using Volocity software (Improvision 
Coverty, UK).
Statistical analysis
Statistical analysis was performed using student t-test 
and ANOVA, where the criteria for statistical significance 
was p < 0.05. For ideal thresholds, the FINDCUT macro 
developed by Jayawant N. Mandrekar et al. from Mayo 
Clinic (http://www2.sas.com/proceedings/sugi28/261-28.
pdf) was used, which identifies the optimal cut off point for 
a continuous variable that predicts time to event outcomes, 
in our case CAI and %CA.
ACkNOwLEDgMENTS
The authors would like to thank Shrikant Pawar 
for in silico gene expression analysis and Alice Cheng 
for technical assistance with experiments. This study 
was supported by grants to RA from the National 
Cancer Institute at the National Institutes of Health (U01 
CA179671, R01 CA169127).
Oncotarget10496www.impactjournals.com/oncotarget
CONFLICTS OF INTEREST STATEMENT
The authors declare that there are no conflicts of 
interests.
REFERENCES
1. Mersin H, Yildirim E, Berberoglu U, Gulben K. The 
 prognostic importance of triple negative breast carcinoma. 
Breast. 2008; 17:341–346.
2. Kaplan HG, Malmgren JA, Atwood M. T1N0 triple 
 negative breast cancer: risk of recurrence and adjuvant 
 chemotherapy. Breast J. 2009; 15:454–460.
3. Irvin WJ Jr., Carey LA. What is triple-negative breast 
 cancer? Eur J Cancer. 2008; 44:2799–2805.
4. Lindner R, Sullivan C, Offor O, Lezon-Geyda K, 
Halligan K, Fischbach N, Shah M, Bossuyt V, Schulz V, 
Tuck DP, Harris LN. Molecular phenotypes in triple 
 negative breast cancer from African American patients 
 suggest targets for therapy. PloS one. 2013; 8:e71915.
5. Seong MW, Cho SI, Kim KH, Chung IY, Kang E, Lee JW, 
Park SK, Lee MH, Choi DH, Yom CK, Noh WC, Chang MC, 
Park SS, Kim SW. A multi-institutional study of the preva-
lence of BRCA1 and BRCA2 large genomic rearrangements 
in familial breast cancer patients. BMC Cancer. 2014; 14:645.
6. Scully R. Role of BRCA gene dysfunction in breast and 
ovarian cancer predisposition. Breast cancer research : 
BCR. 2000; 2:324–330.
7. Liu Y, Kulesz-Martin M. p53 protein at the hub of cellular 
DNA damage response pathways through sequence-specific 
and non-sequence-specific DNA binding. Carcinogenesis. 
2001; 22:851–860.
8. Venkitaraman AR. Cancer susceptibility and the functions 
of BRCA1 and BRCA2. Cell. 2002; 108:171–182.
9. Ko MJ, Murata K, Hwang DS, Parvin JD. Inhibition 
of BRCA1 in breast cell lines causes the centrosome 
 duplication cycle to be disconnected from the cell cycle. 
Oncogene. 2006; 25:298–303.
10. Boveri T. Concerning the origin of malignant tumours by 
Theodor Boveri. Translated and annotated by Henry Harris. 
Journal of cell science. 2008; 121:1–84.
11. Mazia D. The chromosome cycle and the centrosome cycle 
in the mitotic cycle. International review of cytology. 1987; 
100:49–92.
12. Khodjakov A, Rieder CL. Centrosomes enhance the 
 fidelity of cytokinesis in vertebrates and are required for 
cell cycle progression. The Journal of cell biology. 2001; 
153:237–242.
13. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. 
Centrosome hypertrophy in human breast tumors: 
 implications for genomic stability and cell polarity. Proc 
Natl Acad Sci U S A. 1998; 95:2950–2955.
14. Gustafson LM, Gleich LL, Fukasawa K, Chadwell J, 
Miller MA, Stambrook PJ, Gluckman JL. Centrosome 
hyperamplification in head and neck squamous cell 
 carcinoma: a potential phenotypic marker of tumor 
 aggressiveness. The Laryngoscope. 2000; 110:1798–1801.
15. Kuo KK, Sato N, Mizumoto K, Maehara N, Yonemasu H, 
Ker CG, Sheen PC, Tanaka M. Centrosome abnormalities in 
human carcinomas of the gallbladder and intrahepatic and 
extrahepatic bile ducts. Hepatology (Baltimore, Md). 2000; 
31:59–64.
16. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome 
abnormalities and chromosome instability occur 
together in pre-invasive carcinomas. Cancer Res. 2003; 
63:1398–1404.
17. Sato N, Mizumoto K, Nakamura M, Maehara N, 
Minamishima YA, Nishio S, Nagai E, Tanaka M. 
Correlation between centrosome abnormalities and 
 chromosomal instability in human pancreatic cancer cells. 
Cancer genetics and cytogenetics. 2001; 126:13–19.
18. Weber RG, Bridger JM, Benner A, Weisenberger D, 
Ehemann V, Reifenberger G, Lichter P. Centrosome 
 amplification as a possible mechanism for  numerical 
 chromosome aberrations in cerebral primitive 
 neuroectodermal tumors with TP53 mutations. Cytogenetics 
and cell genetics. 1998; 83:266–269.
19. Godinho SA, Picone R, Burute M, Dagher R, Su Y, 
Leung CT, Polyak K, Brugge JS, Thery M, Pellman D. 
Oncogene-like induction of cellular invasion from 
 centrosome amplification. Nature. 2014; 510:167–171.
20. Duensing S, Lee BH, Dal Cin P, Munger K. Excessive 
 centrosome abnormalities without ongoing numerical 
 chromosome instability in a Burkitt’s lymphoma. Molecular 
cancer. 2003; 2:30.
21. Nigg EA. Centrosome aberrations: cause or consequence 
of cancer progression? Nature reviews Cancer. 2002; 
2:815–825.
22. Ogden A, Rida PC, Aneja R. Heading off with the 
herd: how cancer cells might maneuver supernumerary 
 centrosomes for directional migration. Cancer metastasis 
reviews. 2013; 32:269–287.
23. Pannu V, Rida PC, Celik B, Turaga RC, Ogden A, 
Cantuaria G, Gopalakrishnan J, Aneja R. Centrosome-
declustering drugs mediate a two-pronged attack on 
 interphase and  mitosis in supercentrosomal cancer cells. 
Cell death &  disease. 2014; 5:e1538.
24. Fried G, Moskovitz M. Treatment decisions in estrogen 
receptor-positive early breast cancer patients with interme-
diate oncotype DX recurrence score results. SpringerPlus. 
2014; 3:71.
25. Cui Y, Deming-Halverson SL, Shrubsole MJ, Beeghly-
Fadiel A, Fair AM, Sanderson M, Shu XO, Kelley MC, 
Zheng W. Associations of hormone-related factors with 
breast cancer risk according to hormone receptor status 
Oncotarget10497www.impactjournals.com/oncotarget
among white and african american women. Clinical breast 
cancer. 2014; 14:417–425.
26. Churpek JE, Walsh T, Zheng Y, Moton Z, Thornton AM, 
Lee MK, Casadei S, Watts A, Neistadt B, Churpek MM, 
Huo D, Zvosec C, Liu F, Niu Q, Marquez R, Zhang J, 
et al. Inherited predisposition to breast cancer among 
African American women. Breast cancer research and 
 treatment. 2014.
27. Lehmann BD, Bauer JA, Chen X, Sanders ME, 
Chakravarthy AB, Shyr Y, Pietenpol JA. Identification 
of human triple-negative breast cancer subtypes 
and  preclinical models for selection of targeted 
 therapies. The Journal of clinical investigation. 2011; 
121:2750–2767.
